Last week, ASCO submitted joint comment letters with the State Affiliates in Connecticut and Washington in support of legislation that would increase the legal age for the purchase of tobacco products to 21. ASCO is committed to policies that will contribute to reducing prevalence of tobacco use to ultimately prevent the occurrence of cancer and other smoking-caused diseases.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO endorsed the bipartisan Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act (H.R. 820/S.292), which would help accelerate research for pediatric cancer and improve care for the 15,780 children diagnosed with cancer in the U.S. every year.
A new program offers health and wellness options for people living with cancer through their local YMCA. LIVESTRONG® at the YMCA is an evidence-based wellness and exercise program that helps adult cancer survivors reclaim their health and well-being following a cancer diagnosis.
The Journal of Oncology Practice’s (JOP) is expanding its diverse content on the day-to-day practice of oncology to include Care Delivery Reviews.
“ASCO congratulates Representative Tom Price for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). Secretary Price has a unique opportunity to shape the availability and quality of care for millions of people with cancer and maintain the nation’s leadership in biomedical research.
ASCO joined a letter from the Ad Hoc Group for Medical Research urging Congress and the Administration to enact a final fiscal year (FY) 2017 spending bill that includes $34.1 billion for the National Institutes of Health (NIH). The letter also asks Congress and the Administration to make the NIH a priority as they consider funding for FY 2018.
CancerLinQ LLC, a wholly owned nonprofit subsidiary ASCO®, has announced that the University of Virginia (UVA) Cancer Center has signed an agreement to participate in the CancerLinQ® platform.
The Centers for Medicare & Medicaid Services (CMS) has extended the attestation deadline for the 2016 Medicare EHR Incentive Program to Monday, March 13, 2017, at 11:59 p.m. PT. Participating providers must attest to the 2016 program requirements before the deadline to avoid a negative payment adjustment in 2018.
With the new Congress and Administration in place, ASCO has been on Capitol Hill monitoring the issues that affect the cancer care community, and educating lawmakers on how best to serve Americans with cancer. In particular, ASCO is closely tracking efforts to repeal and replace the Affordable Care Act (ACA), the discussion on the future of Medicaid, and relevant cabinet appointments.
ASCO’s "Criteria for High-Quality Clinical Pathways in Oncology," is now featured as a special article in the Journal of Oncology Practice. ASCO developed the 15 inter-related criteria to provide an overarching framework for assessing pathway programs in the United States and to guide stakeholders in assessing the quality, utility and integrity of clinical pathways in oncology.
On February 14, SAP’s online course “The Future of Genomics and Precision Medicine” will begin, and enrollment for the free course is now open.
In a congressional briefing on Capitol Hill, ASCO presented Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer, announced immunotherapy 2.0 as the advance of the year, and urged Congress to support increased federal funding for research.
On February 2, 2017, the U.S. Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Company) for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy.
A new study in the Journal of Managed Care & Specialty Pharmacy found that gaps in the quality measures used to assess cancer care may obscure problems in care delivery and lead to missed opportunities to improve patient outcomes.
An American Medical Association (AMA)-led coalition including ASCO and 15 other health care organizations today urged health plans, benefit managers, and other stakeholders to reform utilization management policies, including prior authorization requirements, imposed on medical tests, procedures, devices, and drugs.